News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
GlaxoSmithKline Sues Partner XenoPort, Inc. Over Marketing Allegations on RLS Drug
February 24, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
GlaxoSmithKline (NYSE:GSK) is pushing back against drug partner XenoPort (NASDAQ:XNPT) over claims that GSK is not doing enough to sell the restless-leg syndrome treatment they jointly developed.
Twitter
LinkedIn
Facebook
Email
Print
Legal
Europe
GSK
MORE ON THIS TOPIC
Insights
Austria’s new growth fund could further bolster its dynamic biotech innovation economy
August 11, 2026
·
5 min read
·
Jennifer C. Smith-Parker
Regulatory
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
August 5, 2026
·
3 min read
·
Annalee Armstrong
Insights
Biologics push CMOs/CDMOs to expand sterile fill-finish and prefilled syringe capacity
August 3, 2026
·
2 min read
·
Jennifer C. Smith-Parker
Legal
Novo ordered to face CagriSema fraud claims from shareholders: New Jersey court
July 29, 2026
·
2 min read
·
Tristan Manalac
